Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
From only 80 Jan Aushadhi Kendras in 2014, there are around 11,000 units operating across the country today
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
The institution will be spread over an area of more than 8 acres
Vision loss due to Glaucoma can be prevented if it is detected and treated early
Subscribe To Our Newsletter & Stay Updated
